×

Research and Markets: Competitive Handbook towards Personalized Medicine in Prostate Cancer Report Identifies 227 Drug Targets, Which We Have Organized Into 216 Drug Target Strategies

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/m427tb/competitive) has announced the addition of the "Competitive Handbook towards Personalized Medicine in Prostate Cancer" report to their offering.

BioSeeker builds its analysis on a comprehensive base of 394 prostate cancer drugs from within the portfolio of 222 companies world-wide, from Ceased to Marketed. We have identified 227 drug targets, which we have organized into 216 drug target strategies, and assessed them by four levels:

1. Individual Target: Shows you how individual targets tie into different target strategies and their subsequent R&D progress.

2. Developmental Stage: Shows you the progress and maturation of different target strategies. Identifies which target strategies are new and unique from one developmental stage to the next.

3. Compound Type: Shows you the competitive landscape of target strategies from a compound perspective, including crossover analysis of target strategies among different compound types.

4. Company: Provides a cross-examination of each company's entire pipeline on the basis of its defined drug target strategies, including a Competitive Fall-Out analysis and a corporate pipeline ranking based on 15 parameters.

Companies Mentioned:

Abbott

Active Biotech

Advantagene

Egera

Eterna Zentaris

lchemia

Alethia Biotherapeutics

Allos Therapeutics

AlphaVax

Alseres Pharmaceuticals

Altor BioScience

Ambrilia Biopharma

American Gene Technology International

Amgen

Anavex Life Sciences

AndroBioSys

Biostar

Boehringer Ingelheim

Bristol-Myers Squibb

BTG

Camurus

Cancer Research Technology

Cel-Sci

Celgene

Curaxis

Curis

Cylene Pharmaceuticals

Cytokinetics

Daiichi Sankyo

Debiopharm

Dendreon

Dongkook Pharm

ECI

Eisai

Eli Lilly

Endo Pharmaceuticals

Endocyte

Ensemble Discovery

EntreMed

EpiCept

Esperance Pharmaceuticals

Etubics

EUSA Pharma

Exelixis

Ferring

Formula Pharmaceuticals

Gilead Sciences

GlaxoSmithKline

GlycoGenesys

Got-a-Gene

GP Pharm

Green Cross

GTx

Harbor BioSciences

Hoffmann-La Roche

Human Genome Sciences

IGF Oncology

Immunocore

ImmunoGen

Isis Pharmaceuticals

Ivy Medical Chemicals

Johnson & Johnson

Karo Bio

Kinex

Kyowa Hakko Kirin

Leo

Ligand

Lorus Therapeutics

MediGene

Nippon Shinyaku

Non-industrial Sources

Northwest Biotherapeutics

Novacea

Novartis

Oncothyreon

Oncovir

Orion Pharma

Paladin Labs

Pantarhei Bioscience

Pepscan Therapeutics

Pfizer

ProStrakan

Q Chip

QLT

Receptor BioLogix

Regeneron

Regulon

Rexahn

SGX Pharmaceuticals

Shire

Siena Biotech

Soligenix

Sophiris Bio

SRI International

Supratek Pharma

Switch Pharma

Synta Pharmaceuticals

Taiho

Takeda

Tapestry Pharmaceuticals

Twinstrand Therapeutics

Unigene

United Biomedical

Vaxon Biotech

Velacor Therapeutics

Xerion

Xoma

YM BioSciences

Zydus Cadila

For more information visit http://www.researchandmarkets.com/research/m427tb/competitive

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Prostate Cancer

Source: Research and Markets